Patients with multiple sclerosis (MS) almost always experience effects in the visual pathway; and thus, visual dysfunction is not only common but also highly relevant. The visual pathway represents a model of acute focal central nervous system (CNS) damage, through acute optic neuritis and retinal periphlebitis, as well as a model of chronic, diffuse CNS damage through chronic retinopathy and optic neuropathy. The optic pathway can be accurately evaluated in detail, due to the availability of highly sensitive imaging techniques (e.g. magnetic resonance imaging or optical coherent tomography) or electrophysiological tests (multifocal visual evoked potentials or electroretinography). These techniques allow the interactions between the different processes at play to be evaluated, such as inflammation, demyelination, axonal damage and neurodegeneration. Moreover, these features mean that the visual pathway can be used as a model to test new neuroprotective or regenerative therapies.
BalkLJTwiskJWSteenwijkMD. A dam for retrograde axonal degeneration in multiple sclerosis?J Neurol Neurosurg Psychiatry2014; 85: 782–789.
2.
MowryEMLoguidiceMJDanielsAB. Vision related quality of life in multiple sclerosis: Correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry2009; 80: 767–772.
3.
BalcerLJBaierMLCohenJA. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology2003; 61: 1367–1373.
4.
SaidhaSSycSBDurbinMK. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography-derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler2011; 17: 1449–1463.
5.
WuGFSchwartzEDLeiT. Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology2007; 69: 2128–2135.
6.
BalcerLJGalettaSLCalabresiPA. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology2007; 68: 1299–1304.
7.
VillosladaPCuneoAGelfandJ. Color vision is strongly associated with retinal thinning in multiple sclerosisMult Scler2012; 18: 991–999.
8.
Martinez-LapiscinaEHOrtiz-PerezSFraga-PumarE. Colour vision impairment is associated with disease severity in multiple sclerosis. Mult Scler2014; [Epub ahead of print] PMID: 24399824.
9.
KlistornerAArvindHNguyenT. Axonal loss and myelin in early ON loss in postacute optic neuritis. Ann Neurol2008; 64: 325–331.
10.
KlistornerAArvindHNguyenT. Fellow eye changes in optic neuritis correlate with the risk of multiple sclerosis. Mult Scler2009; 15: 928–932.
11.
ForooghianFSprouleMWestallC. Electroretinographic abnormalities in multiple sclerosis: Possible role for retinal autoantibodies. Doc Ophthalmol2006; 113: 123–132.
12.
HokazonoKRazaASOyamadaMK. Pattern electroretinogram in neuromyelitis optica and multiple sclerosis with or without optic neuritis and its correlation with FD-OCT and perimetry. Doc Ophthalmol2013; 127: 201–215.
13.
FrohmanTCBehSCSaidhaS. Optic nerve head component responses of the multifocal electroretinogram in MS. Neurology2013; 81: 545–551.
14.
GelfandJMGoodinDSBoscardinWJ. Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PloS ONE2012; 7: e36847.
15.
GabilondoIMartinez-LapiscinaEHMartinez-HerasE. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol2014; 75: 98–107.
CostelloFCouplandSHodgeW. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol2006; 59: 963–969.
18.
RoccaMAMesarosSPreziosaP. Wallerian and trans-synaptic degeneration contribute to optic radiation damage in multiple sclerosis: A diffusion tensor MRI study. Mult Scler2013; 19: 1610–1617.
19.
GreenAJMcQuaidSHauserSL. Ocular pathology in multiple sclerosis: Retinal atrophy and inflammation irrespective of disease duration. Brain2010; 133: 1591–601.
20.
SepulcreJMurie-FernandezMSalinas-AlamanA. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology2007; 68: 1488–1494.
21.
ToledoJSepulcreJSalinas-AlamanA. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler2008; 14: 906–912.
22.
SaidhaSSotirchosESOhJ. Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurology2013; 70: 34–43.
23.
Garcia-MartinEPoloVLarrosaJM. Retinal layer segmentation in patients with multiple sclerosis using spectral domain optical coherence tomography. Ophthalmology2014; 121: 573–579.
24.
SaidhaSSotirchosESIbrahimMA. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: A retrospective study. Lancet Neurol2012; 11: 963–972.
25.
GelfandJMNolanRSchwartzDM. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain2012; 135: 1786–1793.
26.
BurggraaffMCTrieuJDe Vries-KnoppertWA. The clinical spectrum of microcystic macular edema. Invest Ophthalmol Vis Sci2014; 55: 952–961.
27.
SepulcreJGoñiJMasdeuJC. Contribution of white matter lesions to grey matter atrophy in multiple sclerosis: Evidence from voxel-based analysis of T1 lesions in the visual pathway. Arch Neurol2009; 66: 173–179.
28.
MelziLRoccaMAMarzoliSB. A longitudinal conventional and magnetization transfer magnetic resonance imaging study of optic neuritis. Mult Scler2007; 13: 265–268.
KolbeSCMarriottMWaltA. Diffusion tensor imaging correlates of visual impairment in multiple sclerosis and chronic optic neuritis. Invest Ophthalmol Vis Sci2012; 53: 825–832.
31.
HeideACKraftGHSlimpJC. Cerebral N-acetylaspartate is low in patients with multiple sclerosis and abnormal visual evoked potentials. Am J Neuroradiol1998; 19: 1047–1054.
32.
GalloAEspositoFSaccoR. Visual resting-state network in relapsing–remitting MS with and without previous optic neuritis. Neurology2012; 79: 1458–1465.
33.
JenkinsTMToosyATCiccarelliO. Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol2010; 67: 99–113.
34.
HeesenCBohmJReichC. Patient perception of bodily functions in multiple sclerosis: Gait and visual function are the most valuable. Mult Scler2008; 14: 988–991.
35.
Ortiz-PerezSMartinez-LapiscinaEHGabilondoI. Retinal periphlebitis is associated with multiple sclerosis severity. Neurology2013; 81: 877–881.
36.
KlistornerAArvindHGarrickRGrahamSLPaineMYiannikasC. Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. Invest Ophthalmol Vis Sci2010; 51: 2770–2777.
37.
SaidhaSSycSBIbrahimMA. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain2011; 134: 518–533.
38.
AlbrechtPRingelsteinMMullerAK. Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomographyMult Scler2012; 18: 1422–1429.
39.
RazNChokronSBen-HurTLevinN. Temporal reorganization to overcome monocular demyelination. Neurology2013; 81: 702–709.
40.
SuhsKWHeinKSattlerMB. A randomized, double-blind, Phase 2 study of erythropoietin in optic neuritis. Ann Neurol2012; 72: 199–210.
41.
TalmanLSBiskerERSackelDJ. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol2010; 67: 749–760.
42.
MarroMTaubesAAbernathyA. Dynamic molecular monitoring of retina inflammation by in vivo Raman spectroscopy coupled with multivariate analysis. J biophotonics2013; [Epub ahead of print].PMID: 24019106.
